Merck and Moderna’s Personalized mRNA Cancer Vaccine Meets Phase 3 Melanoma Trial Goals

Merck and Moderna reported positive topline results from INTerpath-001, a Phase 3 trial testing the investigational personalized mRNA therapy intismeran autogene with Keytruda (pembrolizumab) after surgery for high-risk melanoma. The combination met the trial’s primary endpoint of recurrence-free survival (RFS) and its key secondary endpoint of distant metastasis-free survival (DMFS) compared with Keytruda alone.

The announcement marks the first reported positive Phase 3 result for an individualized mRNA-based cancer therapy. But it is not yet a complete clinical readout: the companies have not published the numerical effect size needed to judge how large or durable the benefit is.

What INTerpath-001 tested

The trial enrolled 1,137 patients with completely resected stage IIB to IV melanoma who had not previously received systemic treatment. Participants were randomized to receive either intismeran autogene plus Keytruda or Keytruda alone as adjuvant treatment—therapy given after surgery to reduce the risk of the cancer returning.

At a prespecified interim analysis, Merck and Moderna said the combination produced statistically significant and clinically meaningful improvements in both RFS and DMFS. RFS measures the time patients remain free of recurrent melanoma or death; DMFS focuses on recurrence that has spread to distant parts of the body or death.

The companies described the regimen as the first combination in this adjuvant melanoma setting to show significant improvement over Keytruda alone on both measures.

How the personalized mRNA therapy works

Intismeran autogene—also known as V940 or mRNA-4157—is an individualized neoantigen therapy. Rather than using the same vaccine design for every patient, the treatment is created from mutations identified in that person’s tumor.

Its mRNA is intended to provide instructions that help the immune system recognize tumor-specific neoantigens, or abnormal markers created by cancer-related mutations. The therapy is designed to target up to 34 mutations in an individual tumor.

The treatment is therefore not a universal melanoma vaccine and is not currently an approved product. Its potential depends not only on the immune response but also on whether a personalized product can be reliably designed and manufactured for each patient.

What the earlier Phase 2b data showed

The Phase 3 announcement follows encouraging five-year follow-up from the randomized Phase 2b KEYNOTE-942/mRNA-4157-P201 study. In that smaller trial, intismeran autogene plus Keytruda reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% compared with Keytruda alone.

Those findings provided the rationale for the larger confirmatory study. However, the Phase 2b results cannot establish the size of the benefit in INTerpath-001, whose broader stage IIB–IV population and larger sample are being evaluated separately.

The most important Phase 3 details are still missing

Merck and Moderna have released topline conclusions, not the full dataset. The companies have not yet disclosed the Phase 3 hazard ratios, confidence intervals, absolute recurrence or metastasis rates, detailed safety results, length of follow-up or outcomes by disease stage. They plan to present the data at an international medical meeting.

That means several practical questions remain unanswered:

• How large is the absolute benefit, not just the statistical difference?
• Is the effect consistent across stage IIB, IIC, III and IV melanoma?
• How long does the benefit last?
• What adverse effects occur when the vaccine is added to Keytruda?
• Does delaying recurrence eventually translate into longer overall survival?

Overall-survival follow-up is continuing, so the current announcement does not establish that the combination helps patients live longer.

Manufacturing will also matter. Analysts will need information about the time required to create each patient’s therapy, production capacity, reliability and cost before assessing whether the approach can be delivered at scale.

Regulatory and development implications

The positive interim result could support a future regulatory submission, but it is not an approval. Merck and Moderna said they plan to engage with regulators about potential submissions.

The companies previously sought an accelerated-approval pathway, but that effort did not result in approval; the FDA had rejected the request in 2024. The Phase 3 result gives the partners a more substantial basis for discussions, although regulators will still need to review the complete efficacy and safety evidence.

Intismeran autogene is also being evaluated in nine additional trials, including studies involving non-small-cell lung cancer, bladder cancer, renal cell carcinoma and melanoma.

Why the result matters—and why it is too early to call it a new standard

The result is important because it provides the first reported positive Phase 3 evidence for a personalized mRNA cancer vaccine. It suggests that targeting an individual tumor’s neoantigens may add benefit to checkpoint inhibition after surgery.

If the complete dataset confirms a meaningful, durable and tolerable improvement—and if individualized manufacturing proves practical—the combination could influence adjuvant treatment for melanoma and encourage similar approaches in other cancers.

For now, the strongest evidence-based conclusion is narrower: intismeran autogene plus Keytruda met the prespecified RFS and DMFS endpoints in a large Phase 3 melanoma trial. The treatment’s precise clinical value, safety profile, survival impact and commercial feasibility will depend on the detailed data still awaiting release.